Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

These Dangerous World Circumstances and the Prohost Portfolio

March 4, 2022 0

The circumstances that we find the world in today are abnormal. They are extremely intense and …

What Happens to Intellia When the U.S. Patent and Trademark Office Changes Previous Patent Decisions?

March 1, 2022 0

Intellia Therapeutics Loses Technology Patent and Suffers a Selloff A selloff of Intellia Therapeutics (NTLA) stock …

Our Plan as the Stock Market Continues to Plummet

February 17, 2022 2

The Stock Market Continues to Plummet Indeed, the Stock Market continues to decline, losing investors' profits. …

Karyopharm Therapeutics Getting a Boost in the Midst of a Chaotic Market

February 14, 2022 0

We do not dare invest in the stock market at a time when almost all the …

Who Forgot About Enanta Pharmaceuticals?

February 11, 2022 0

Enanta Pharmaceuticals Expectations Expecting Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor …

An Important Milestone for Regenxbio Treatment of Wet AMD

February 8, 2022 0

Regenxbio Good News for wet AMD On January 10, 2022, Regenxbio Inc. (RGNX) announced the initiation of …

Why Intellia Therapeutics Acquisition of Rewrite Therapeutics Is Important

February 7, 2022 0

Intellia Therapeutics Acquires Rewrite Therapeutics The acquisition is, indeed good news. By acquiring Rewrite Therapeutics, Intellia …

Some Ideas About the Falling Stock Market Day

February 3, 2022 0

The Stock Market Today Before the end of 2021 we recognized that investors were not going …

We Are Back

February 1, 2022 2

We Are Back! Thanks to God. Hello to all our subscribers. Our sickness was unanticipated, making …

Celularity Inc NK Cell Therapy CYNK-001 Receives US FDA Fast Track Designation for AML Treatment

December 28, 2021 0

Celularity Inc Celularity Inc. (CELU) announced the U.S. Food and Drug Administration (FDA) has granted Fast …

Important and Encouraging News from Sutro Biopharma Inc

December 27, 2021 0

Sutro Biopharma Inc and Tasly Biopharmaceuticals Exclusive Licensing Agreement for STRO-002 In a press release from …

The FDA Authorized Emergency Use of Pfizer Paxlovid Pills Against COVID-19

December 25, 2021 0

Pfizer Received Emergency Use Authorization from the FDA for Paxlovid Pills for COVID-19 Good news for …

Comprehensive Prohost Letter #448

December 22, 2021 0

Comprehensive Prohost Letter Issues Coronavirus Variant Omicron A lot has happened since the coronavirus variant Omicron …

Gilead Sciences and Arcus Biosciences: Complete Closing of Option Exercises of 3 Programs. See Also: HOLD Put on Lenacapavir Due to Vial Quality Concern

December 22, 2021 0

Gilead Sciences and Arcus Biosciences Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced the closing of …

The FDA Cleared the IND for Erasca Inc Product ERAS-801 for Recurrent Glioblastoma

December 17, 2021 0

Erasca Inc Product ERAS-801 IND Cleared by FDA Erasca Inc (ERAS) announced that the United States Food and …

Arcturus Therapeutics Additional Updates from ARCT-154 and ARCT-165 Clinical Trials and More

December 16, 2021 0

Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings (ARCT) is a clinical-stage mRNA medicines company of enabling technologies with …

Devastated and Resurrected Good Biotech Firms: Theravance Biopharma

December 15, 2021 0

The Market Devastation and Resurrection of Good Biotech Firms Due to the market’s instability that we …

AstraZeneca Granted FDA EUA for Long Acting Antibody Evusheld for Pre-Exposure Prophylaxis of Covid-19

December 9, 2021 0

AstraZeneca Long Acting Antibody Granted FDA EUA for COVID-19 Prevention AstraZeneca (AZN) product Evusheld (tixagevimab co-packaged …

Ionis Pharmaceuticals to Collaborate with AstraZeneca in Treating Transthyretin Amyloidosis with Ionis Product Eplontersen

December 8, 2021 0

Ionis Pharmaceuticals and AstraZeneca in Collaboration to Treat ATTR with Eplontersen Ionis Pharmaceuticals (IONS) announced entering into …

Celldex Therapeutics Dosed the First Patient in a Phase 1 Study of CDX-0159 for Prurigo Nodularis

December 8, 2021 0

Celldex Therapeutics Dosed the First Patient with CDX-0159 for Prurigo Nodularis Celldex Therapeutics (CLDX) announced that …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

These Dangerous World Circumstances and the Prohost Portfolio

What Happens to Intellia When the U.S. Patent and Trademark Office Changes Previous Patent Decisions?

Our Plan as the Stock Market Continues to Plummet

Karyopharm Therapeutics Getting a Boost in the Midst of a Chaotic Market

Who Forgot About Enanta Pharmaceuticals?

An Important Milestone for Regenxbio Treatment of Wet AMD

Why Intellia Therapeutics Acquisition of Rewrite Therapeutics Is Important

Some Ideas About the Falling Stock Market Day

We Are Back

Celularity Inc NK Cell Therapy CYNK-001 Receives US FDA Fast Track Designation for AML Treatment

Important and Encouraging News from Sutro Biopharma Inc

The FDA Authorized Emergency Use of Pfizer Paxlovid Pills Against COVID-19

Comprehensive Prohost Letter #448

Gilead Sciences and Arcus Biosciences: Complete Closing of Option Exercises of 3 Programs. See Also: HOLD Put on Lenacapavir Due to Vial Quality Concern

The FDA Cleared the IND for Erasca Inc Product ERAS-801 for Recurrent Glioblastoma

Arcturus Therapeutics Additional Updates from ARCT-154 and ARCT-165 Clinical Trials and More

Devastated and Resurrected Good Biotech Firms: Theravance Biopharma

AstraZeneca Granted FDA EUA for Long Acting Antibody Evusheld for Pre-Exposure Prophylaxis of Covid-19

Ionis Pharmaceuticals to Collaborate with AstraZeneca in Treating Transthyretin Amyloidosis with Ionis Product Eplontersen

Celldex Therapeutics Dosed the First Patient in a Phase 1 Study of CDX-0159 for Prurigo Nodularis